Vertex Pharmaceuticals Incorporated (VRTX)
Pre-market:
| Previous close | 396.20 |
| Open | 396.20 |
| Bid | 374.62 x 100 |
| Ask | 393.06 x 100 |
| Day's range | 391.70 - 396.69 |
| 52-week range | 320.01 - 448.40 |
| Volume | |
| Avg. volume | 1,131,222 |
| Market cap | 101.525B |
| Beta (5Y monthly) | 0.37 |
| PE ratio (TTM) | 28.26 |
| EPS (TTM) | 13.90 |
| Earnings date | 06 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 465.42 |
ZacksVertex (VRTX) to Report Q1 Earnings: What's in the Cards?
Vertex's (VRTX) revenues in the first quarter of 2024 are likely to have been driven by the robust sales of its lead CF product, Trikafta/Kaftrio.
ZacksVertex Pharmaceuticals (VRTX) Earnings Expected to Grow: Should You Buy?
Vertex (VRTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Business WireVertex Announces European Commission Approval for KALYDECO® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older
LONDON, April 26, 2024--Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R.
